Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: GlobeNewswire
Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line results for fully enrolled Phase 2 TOIVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for cutaneous venous malformations remain on track for mid-December 2025 Top-line results for fully enrolled Phase 3 SELVA trial evaluating QTORIN™ rapamycin for microcystic lymphatic malformations remain on track for the first quarter of 2026 Expanded QTORIN™ rapamycin’s development into clinically significant angiokeratomas, a rare and debilitating lymphatic disease with no FDA-approved therapies, with Phase 2 study initiation anticipated in second half of 2026 Announced new QTORIN™ product candidate, QTORIN™ pitavastatin, for the treatment of disseminated superficial actinic porokeratosis, a rare, chronic, and pre-cancerous genetic skin disease with no FDA-approved th
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) was given a new $145.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $143.00 price target on the stock, up previously from $92.00.MarketBeat
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 11/21/25 - Form 4
- 11/19/25 - Form 144
- 11/14/25 - Form SCHEDULE
- PVLA's page on the SEC website